Hematologic Oncology Update
Hematologic Oncology Update is a medical education podcast hosted by Dr. Neil Love. Each episode features one-on-one interviews with leading hematology and oncology experts. The discussions focus on recent advances in the treatment of blood cancers, including leukemias, lymphomas and multiple myeloma. The goal is to give practicing medical oncologists practical perspectives that help them provide optimal patient care. Content is aimed at clinicians and centers on translating new research into everyday clinical practice.
Episodes
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2026 Annual Meeting
Featuring perspectives from Dr Meletios-Athanasios (Thanos) C Dimopoulos, Dr Robert Z Orlowski and Dr Noopur Raje, moderated by Dr Orlowski, including the following topics:Introduction (0:00)New and Emerging Strategies with Bispecific Antibodies in Multiple Myeloma (MM) — Dr Raje (2:20)Utility of Antibody-Drug Conjugates for Relapsed/Refractory (R/R) MM — Dr Orlowski (23:33)Potential Role of Cereb
Chronic Lymphocytic Leukemia — Investigators Discuss Optimal Management
Featuring perspectives from Dr Catherine C Coombs and Dr Matthew S Davids, including the following topics:Introduction (0:00)Minimal Residual Disease Assays in Community-Based Practice (1:24)New Developments in Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Davids (8:12)Richter Transformation (30:43)Selection and Sequencing of Therapies for Relapsed/Refractory CLL — Dr Coombs (34:49)
Diffuse Large B-Cell Lymphoma — An Interview with Dr L Elizabeth Budde on Employing CD20 x CD3 Bispecific Antibodies
Featuring an interview with Dr L Elizabeth Budde, including the following topics:Considerations for selecting between bispecific antibodies (BsAbs); monotherapy versus combination therapy (0:00)Management of BsAb-induced cytokine release syndrome and other toxicities (7:35)Use of BsAbs in the front-line treatment of diffuse large B-cell lymphoma (DLBCL); key findings from the Phase II MorningSun s
Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Ann LaCasce and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Treatment (1:33)Bispecific Antibodies and Chimeric Antigen Receptor T-Cell Therapy (20:36)CME information and select publications
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Conjunction with the American Oncology Network
Featuring perspectives from Dr Farrukh T Awan and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:Introduction (0:00)First-Line Therapy (2:48)Relapsed/Refractory Disease (39:30)CME information and select publications
Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Reviewing Recent Datasets from the 2026 ASCO Annual Meeting and EHA2026 Congress
Featuring perspectives from Dr Brad S Kahl, Dr Jeff Sharman and Dr Tanya Siddiqi, including the following topics:Introduction (0:00)Trials in Progress (1:12)Chronic Lymphocytic Leukemia (7:09)Diffuse Large B-Cell Lymphoma (32:35)Mantle Cell Lymphoma (58:25)Follicular Lymphoma (1:14:49)CME information and select publications
Antibody-Drug Conjugates for Multiple Myeloma — An Interview with Dr Douglas W Sborov
Featuring an interview with Dr Douglas W Sborov, including the following topics:DREAMM-2 trial outcomes and clinical development of antibody-drug conjugates for multiple myeloma (MM); mechanism of action of belantamab mafodotin (belamaf) and predictors of response to treatment (0:00)Perspectives on findings from the Phase III DREAMM-7 trial of belamaf combined with bortezomib/dexamethasone for rel
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus
Featuring an interview with Prof Andreas Hochhaus, including the following topics:Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)Potential mechanisms of adverse events documented with TKIs (
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 4
Featuring perspectives from Prof John Seymour and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A woman in her mid 50s with multiple sclerosis, hypertension, IGHV-unmutated chronic lymphocytic leukemia (CLL) with an SF3B1 mutation and autoimmune hemolytic anemia receives acalabrutinib/venetoclax/obinutuzumab (0:00)Case: A man in his
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 3
Featuring perspectives from Prof John Seymour, including the following topics:Safety of fixed-duration acalabrutinib/venetoclax for chronic lymphocytic leukemia (CLL) (0:00)Venetoclax re-treatment and ongoing trials with acalabrutinib/venetoclax for CLL (6:21)First-line treatment with sonrotoclax and zanubrutinib for CLL (13:10)CME information and select publications
Relapsed/Refractory Chronic Lymphocytic Leukemia — A Grand Rounds Program
Featuring perspectives from Dr William G Wierda, including the following topics:Introduction: Overview of the Grand Rounds Chronic Lymphocytic Leukemia Initiative (0:00)Sequencing Road Map (12:39)Key Datasets — Pirtobrutinib (21:08)Investigator Survey (34:09)Chimeric Antigen Receptor T-Cell Therapy (45:08)Other Novel Therapy Approaches (49:58)EHA 2026 (54:45)CME information and select publications
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Matthew Matasar and Dr Sonali M Smith, including the following topics:Introduction: Lymphoma Survivorship (0:00)Novel Treatment Approaches for Diffuse Large B-Cell Lymphoma — Dr Matasar (6:49)Novel Treatment Approaches for Follicular Lymphoma and Mantle Cell Lymphoma — Dr Smith (32:14)CME information and select publications
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Featuring perspectives from Dr Amrita Krishnan and Dr Robert Z Orlowski, including the following topics:Introduction (00:00)Up-Front Progression-Free Survival for Standard-Risk Disease — 2006, 2016 (1:47)Current and Emerging Therapeutic Approaches — Dr Orlowski (10:34)Chimeric Antigen Receptor T-Cell Therapy, Bispecific Antibodies and Antibody-Drug Conjugates — Dr Krishnan (27:15)ASCO and EHA 2026
Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Roles of CAR T-Cell Therapy and Bispecific Antibodies
Featuring perspectives from Dr Jeremy S Abramson, Dr Joshua Brody, Dr Manali Kamdar, Dr Tycel Phillips and Dr Jason Westin, moderated by Dr Abramson, including the following topics:Introduction (0:00)Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (2:16)Bispecific Antibody Therapy for DLBCL — Dr Westin (27:21)CAR T-Cell Therapy for Other Lymphom
Myelofibrosis — Proceedings from a Webinar Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Prof Claire Harrison and Dr Raajit K Rampal, including the following topics:Introduction (0:00)The Biopathophysiology of Myelofibrosis (MF) (2:19)Current and Future Clinical Decision-Making in the Absence of Severe Cytopenias — Prof Harrison (7:49)Managing MF for Patients with Anemia and Thrombocytopenia — Dr Rampal (35:00)Upcoming at European Hematology Association (EH
Chronic Lymphocytic Leukemia — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Jeremy S Abramson, Dr John N Allan, Dr Bita Fakhri, Dr Shuo Ma and Dr Mazyar Shadman, moderated by Dr Abramson, including the following topics:Introduction (0:00)Current and Future Role of Continuous Bruton Tyrosine Kinase (BTK) Inhibitor Therapy for Previously Untreated Chronic Lymphocytic Leukemia (CLL) — Dr Fakhri (2:22)Available and Emerging Approaches to Time-Li
For Oncology Nurses: Relapsed/Refractory Multiple Myeloma — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Beth Faiman, Dr Natalie S Callander, Dr Hans Lee and Dr Mary Steinbach, moderated by Dr Callander, including the following topics:Introduction (00:00)Role of Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory (R/R) MM (3:44)Role of BCMA- and Non-BCMA-Targeted Bispecific Antibodies in R/R MM (27:00)Utility of Belantamab Mafodotin in R/R MM (49:29)Potentia
Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1
Featuring perspectives from Dr Mazyar Shadman, including the following topics:The CLL17 trial: Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia (CLL) (0:00)The AMPLIFY trial: Fixed-duration acalabrutinib combinations for untreated CLL (5:31)Zanubrutinib-based therapy for treatment-naïve CLL (12:32)CME information and select publications
Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2
Featuring perspectives from Dr Mazyar Shadman and cases from Dr Daniel Ermann, Dr Shazia Nakhoda and Dr Mahesh Swaminathan, including the following topics:Case: A man in his mid 40s with chronic lymphocytic leukemia (CLL) receives acalabrutinib/venetoclax as part of the MAJIC trial (0:00)Case: A man in his early 70s with TP53-mutated CLL expresses concern about side effects associated with zanubru
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Melissa Alsina, Dr Hans Lee, Dr Sagar Lonial and Dr Paul G Richardson, moderated by Dr Lonial, including the following topics:Introduction (0:00)Integrating Bispecific Antibodies into the Management of Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Lee (1:45)Current Utility of Antibody-Drug Conjugates for MM — Dr Lonial (33:55)Potential Role of Cereblon E3 Liga
For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress
Featuring perspectives from Dr Farrukh T Awan, Dr Brad S Kahl, Ms Robin Klebig and Ms Mollie Moran, moderated by Dr Kahl, including the following topics:Introduction: Biology of Non-Hodgkin Lymphoma (NHL) (00:00)Current Role of CD20 x CD3 Bispecific Antibodies in NHL (4:49)Role of Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma (DLBCL) (27:48)Optimal Application of Loncastuximab Tesirine for
Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting
Featuring perspectives from Dr Christopher Flowers, Dr Matthew Lunning, Dr Sonali M Smith and Dr Brad S Kahl, moderated by Dr Kahl, including the following topics:Rational Incorporation of CD79b-Targeted Antibody-Drug Conjugates into the Management of Newly Diagnosed and Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Flowers (00:00)Clinical Utility of CD19-Directed Monoclonal
Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Courtney D DiNardo and Dr Harry Paul Erba, including the following topics:Introduction (0:00)Current Management Approaches for FLT3- and IDH-Mutated Acute Myeloid Leukemia (AML) — Dr DiNardo (9:44)Current and Future Role of Menin Inhibitors for Patients with AML — Dr Erba (32:07)CME information and select publications
Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Anthony M Hunter and Dr Abdulraheem Yacoub, including the following topics:Introduction (0:00)Systemic Mastocytosis — Dr Hunter (9:33)Myelofibrosis — Dr Yacoub (29:40)CME information and select publications
Multiple Myeloma — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Hans Lee and Dr Noopur Raje, including the following topics:Introduction (0:00)Integrating Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies into the Management of Relapsed/Refractory Multiple Myeloma (R/R MM) — Dr Raje (4:30)Antibody-Drug Conjugates and Other Emerging Therapies for R/R MM — Dr Lee (28:33)CME information and select publications
Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr John N Allan and Dr Adam Kittai, including the following topics:Introduction (0:00)Current Management of Newly Diagnosed Chronic Lymphocytic Leukemia — Dr Allan (8:47)Noncovalent Bruton Tyrosine Kinase Inhibitors and Other Novel Strategies — Dr Kittai (38:14)CME information and select publications
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit
Featuring perspectives from Dr Manali Kamdar, Dr Krish Patel and Dr Gilles Salles, including the following topics:Introduction (0:00)Antibody-Drug Conjugates and Other Novel Strategies for the Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Prof Salles (7:05)Current and Future Role of Monoclonal and Bispecific Antibodies in the Management of DLBCL — Dr Patel (26:21)Chimeric Antigen Receptor
Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances
Dr Jennifer R Brown and Prof Wojciech Jurczak discuss the selection and sequencing of Bruton tyrosine kinase-targeted therapy for patients with chronic lymphocytic leukemia and summarize major advances in the treatment landscape over the past year.CME information and select publications here.
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML.CME information and select publications here.
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma.CME information and select publications here.
Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah
Dr Bijal Shah from Moffitt Cancer Center in Tampa, Florida, discusses the role of BiTEs in the management of ALL.CME information and select publications here.
Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting
Prof Constantine Tam from Monash University in Melbourne, Australia, reviews recent datasets and discusses their implications for current and future management of chronic lymphocytic leukemia.CME information and select publications here.
Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia.CME information and select publications here.
Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators
Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss the potential role of CELMoDs in the management of multiple myeloma, supporting clinical data and ongoing investigations.CME information and select publications here.
Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.
Immune Thrombocytopenia — ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston, Dr Cindy Neunert from Columbia University Irving Medical Center in New York and Prof Francesco Zaja from ASUGI in Trieste, Italy discuss cases of immune thrombocytopenia and recent findings from the 2025 ASH Annual Meeting.CME information and select publications here.
Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review
Dr Sagar Lonial from Winship Cancer Institute in Atlanta, Georgia, discusses recent clinical developments with BCMA-targeted therapy and investigational agents for relapsed/refractory multiple myeloma presented at ASH 2025.CME information and select publications here.
Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review
Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.
Relapsed/Refractory Multiple Myeloma — ASH 2025 Review
Dr Sagar Lonial from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr María-Victoria Mateos from the University Hospital of Salamanca in Salamanca, Spain, discuss cases of relapsed/refractory multiple myeloma and recentresearch findings from the 2025 ASH Annual Meeting. CME information and select publications here.
Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Nancy L Bartlett from the Washington University School of Medicine, Dr John P Leonard from the Perlmutter Cancer Center, Dr Matthew Matasar from Rutgers Cancer Institute, Dr Loretta J Nastoupil from Southwest Oncology and Prof Pier Luigi Zinzani from the University of Bologna in Italy discuss recent updates on available and novel treatment strategies for follicular lymphoma and diffuse large B-
Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Prof Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust in London, Dr Andrew T Kuykendall from Moffitt Cancer Center, Dr Stephen T Oh from the Washington University School of Medicine, Dr Jeanne Palmer from the Mayo Clinic School of Medicine and Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center discuss recent updates on available and novel treatment strategies for myelofib
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Matthew S Davids from Dana-Farber Cancer Institute, Dr Bita Fakhri from Stanford University School of Medicine, Prof Constantine Tam from Alfred Health in Melbourne, Australia, and Dr Jennifer Woyach from The Ohio State University Comprehensive Cancer Center review the treatment landscape for patients with chronic lymphocytic leukemia and discuss current research immediately before the 67th ASH
Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Dr Harry Paul Erba from the Duke Cancer Institute, Dr Amir Fathi from Massachusetts General Hospital, Dr Tara L Lin from The University of Kansas Medical Center, Dr Alexander Perl from the University of Pennsylvania’s Abramson Cancer Center and Dr Eytan M Stein from Memorial Sloan Kettering Cancer Center discuss recent data surrounding the management of AML and their perspectives on clinical appli
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. CME information and select publications here.
CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here.
Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning
Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy. CME information and select publications here.
Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. CME information and select publications here.
Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA
Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia. CME information and select publications here.
Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. CME information and select publications here.
Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma. CE information and select publications here.
Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors
Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple
Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy
Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here.
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management
Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer the
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason
Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. NCPD information and select publications here.
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu
Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. NCPD information and select publications here.
Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients
Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here.
Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma
For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relapsed/refractory multiple myeloma. Educational a
Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations
Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. CME information and select publications here.
Multiple Myeloma — Optimizing the Selection of First-Line Therapy
Prof Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. CME information and select publications here.
Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. CME information and select publications here.
Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting
Dr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. CME information and select publications here.
For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress
Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.
Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehensive Cancer Center in Duarte, California, discuss
For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress
Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.
For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress
Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here.
IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies
Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas. CME information and select publications here.
Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances
Prof Meletios-Athanasios (Thanos) C Dimopoulos from the National and Kapodistrian University of Athens and Alexandra Hospital in Athens, Greece, and Dr Robert Z Orlowski from The University of Texas MD Anderson Cancer Center in Houston, Texas, provide their perspectives on relevant new clinical data in multiple myeloma and their application to disease treatment. CME information and select pub
Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances
Professor Claire Harrison from the Guy’s and St Thomas’ NHS Foundation Trust in London, United Kingdom, and Dr John Mascarenas from The Tisch Cancer Institute in New York, New York, provide their perspectives on relevant new clinical data in myelofibrosis and discuss their application to treatment. CME information and select publications here.
Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances
Dr Stephen Ansell from Mayo Clinic in Rochester, Minnesota, and Dr Brian Hill from Cleveland Clinic Taussig Cancer Institute in Ohio summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with non-Hodgkin lymphoma. CME information and select publications here.
Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of systemic mastocytosis and myelofibrosis. CME information and select publications here.
Multiple Myeloma — Fourth Annual National General Medical Oncology Summit
Clinical investigators discuss available data guiding the management of multiple myeloma. CME information and select publications here.
Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.
Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting
Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here.
